Amarantus Bioscience Holdings Inc (AMBS)

[Inoviorulez]

I know it sucks to wait but MANF study data will come when it pours in. In the meantime though the company is making the right decision with advancing Lympro first. With Lympro the company can make millions of dollars early while under CLIA, while at the same time building up the therapeutic pipeline MANF etc. so management knows what they are doing, you have to put things into perspective.

Under CLIA with some revenue AMBS may not even have to dilute shareholders any more. It's a win win situation for the company and for shareholders. So Lympro as first priority is a wise decision. MANF test results will come as they are completed!